Literature DB >> 15069462

What exactly is a mood stabilizer?

L Trevor Young.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15069462      PMCID： PMC383340     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  9 in total

1.  Practice guideline for the treatment of patients with bipolar disorder (revision).

Authors: 
Journal:  Am J Psychiatry       Date:  2002-04       Impact factor: 18.112

2.  Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania.

Authors:  T Suppes; A Webb; B Paul; T Carmody; H Kraemer; A J Rush
Journal:  Am J Psychiatry       Date:  1999-08       Impact factor: 18.112

Review 3.  Finding the intracellular signaling pathways affected by mood disorder treatments.

Authors:  Joseph T Coyle; Ronald S Duman
Journal:  Neuron       Date:  2003-04-24       Impact factor: 17.173

Review 4.  The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry.

Authors:  Bruno Müller-Oerlinghausen; Anne Berghöfer; Bernd Ahrens
Journal:  Can J Psychiatry       Date:  2003-08       Impact factor: 4.356

5.  Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.

Authors:  Mauricio Tohen; Terence A Ketter; Carlos A Zarate; Trisha Suppes; Mark Frye; Lori Altshuler; John Zajecka; Leslie M Schuh; Richard C Risser; Eileen Brown; Robert W Baker
Journal:  Am J Psychiatry       Date:  2003-07       Impact factor: 18.112

Review 6.  Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials.

Authors:  John R Geddes; Sally Burgess; Keith Hawton; Kay Jamison; Guy M Goodwin
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

7.  Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.

Authors:  Mauricio Tohen; Eduard Vieta; Joseph Calabrese; Terence A Ketter; Gary Sachs; Charles Bowden; Philip B Mitchell; Franca Centorrino; Richard Risser; Robert W Baker; Angela R Evans; Karin Beymer; Sanjay Dube; Gary D Tollefson; Alan Breier
Journal:  Arch Gen Psychiatry       Date:  2003-11

Review 8.  What is a "mood stabilizer"? An evidence-based response.

Authors:  Mark S Bauer; Landis Mitchner
Journal:  Am J Psychiatry       Date:  2004-01       Impact factor: 18.112

9.  Atypical antipsychotics attenuate neurotoxicity of beta-amyloid(25-35) by modulating Bax and Bcl-X(l/s) expression and localization.

Authors:  Zelan Wei; Darrell D Mousseau; J Steven Richardson; Lillian E Dyck; Xin-Min Li
Journal:  J Neurosci Res       Date:  2003-12-15       Impact factor: 4.164
  9 in total
  7 in total

1.  Fronto-limbic dysfunction in mania pre-treatment and persistent amygdala over-activity post-treatment in pediatric bipolar disorder.

Authors:  Alessandra M Passarotti; John A Sweeney; Mani N Pavuluri
Journal:  Psychopharmacology (Berl)       Date:  2011-03-10       Impact factor: 4.530

2.  Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression.

Authors:  Joanna Szarmach; Wiesław Jerzy Cubała; Adam Włodarczyk; Maria Gałuszko-Węgielnik
Journal:  Neuropsychiatr Dis Treat       Date:  2020-10-29       Impact factor: 2.570

Review 3.  Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review.

Authors:  Hans-Jürgen Möller; Heinz Grunze; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-04       Impact factor: 5.270

4.  CACNA1C Risk Variant and Mood Stabilizers Effects in the Prefrontal Cortical Thickness of Mexican Patients with Bipolar Disorder.

Authors:  Alejandra Monserrat Rodríguez-Ramírez; Fátima Meza-Urzúa; Valente Cedillo-Ríos; Claudia Becerra-Palars; Joanna Jiménez-Pavón; Ingrid Pamela Morales-Cedillo; Marco Antonio Sanabrais-Jiménez; Sandra Hernández-Muñoz; Beatriz Camarena-Medellín
Journal:  Neuropsychiatr Dis Treat       Date:  2020-05-12       Impact factor: 2.570

5.  Factors associated with high-dose antipsychotic prescriptions in outpatients with schizophrenia: An analysis of claims data from a Japanese prefecture.

Authors:  Tatsuichiro Takahashi; Tetsuya Otsubo; Susumu Kunisawa; Yuichi Imanaka
Journal:  Neuropsychopharmacol Rep       Date:  2020-05-26

6.  The diagnostic dilemma: why we need to change how we diagnose bipolar disorder in children.

Authors:  Daniel Dickstein
Journal:  Cerebrum       Date:  2010-11-10

7.  Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression.

Authors:  Adam Włodarczyk; Wiesław J Cubała; Maria Gałuszko-Węgielnik; Joanna Szarmach
Journal:  Ther Adv Psychopharmacol       Date:  2021-05-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.